Ocular Therapeutix announced the appointment of Donald Notman as Chief Financial Officer, effective immediately. Mr. Notman will replace interim CFO George Migausky and will be responsible for all strategic financial planning and reporting and investor relations. He will also support the company’s business development initiatives. Mr. Notman has more than 20 years of financial operations and senior-level investment banking experience.
“Donald brings an extensive financial background as well as a wealth of experience and relationships ideally suited to Ocular Therapeutix,” Antony Mattessich, President and Chief Executive Officer, said in a company news release. “He will be a strong complement to our existing team and his expertise will be invaluable as we focus our efforts on leveraging our hydrogel technology platform to build a leading biopharmaceutical company. We would also like to thank George for his many contributions as interim CFO over the last several months and wish him all the best.”
Prior to joining Ocular Therapeutix, Mr. Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics, where he led the company’s financial operations, business development activities, and strategic planning functions. Previously, Mr. Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was involved in the build-out of the firm’s healthcare investment banking capabilities. Before joining Leerink, Mr. Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Mr. Notman received his M.B.A. from The Tuck School of Business at Dartmouth College and his B.A. in Economics from Middlebury College.
“Ocular’s innovative hydrogel technology platform along with the team’s formulation and product development expertise provide Ocular with the ability to leverage the platform in a number of ways to advance the company,” Mr. Notman said in the news release. “I look forward to applying my background and expertise to help Ocular achieve its full potential.”